The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

Inclusion Criteria: * Three unexplained consecutive spontaneous abortions before the 10th week of gestation (the recurrent embryo loss subgroup) - OR - * One unexplained death of a morphologically normal fetus (fetal loss) at or after the 10th week of gestation (fetal loss subgroup). * Women in the APS subgroup: persistently positive for LA, and/or aCL and/or aBeta2GP1 * Women initiating a new pregnancy during the 18 month observational period after obstetric APS diagnosis Exclusion Criteria: * Any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition * Women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal factors, or associated with paternal or maternal chromosomal causes * Seropositivity for HIV, hepatitis B or C * Women with antithrombin, protein C, or protein S deficiency, and women with abnormal fibrinogen or with the JAK2 V617F mutation were further excluded.